ArticleJournal of molecular medicine (Berlin, Germany)2020

The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.

Jianxuan Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.